Scientists have proved that nano-formulation of Melatonin, the hormone produced by the brain in response to darkness, showed improved antioxidative and neuroprotective properties and could be a potential therapeutic solution for Parkinson’s disease (PD).
Key Points
- Parkinson’s disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain due to aggregation of synuclein protein inside it.
- Available medications can only minimize the symptoms but cannot cure the disease and this underlines the need to develop better therapeutic solutions for the disease.
- A group of researchers from Institute of Nano Science and Technology (INST) Mohali used human serum albumin nano-formulation to deliver the drug to the brain and studied the molecular mechanism behind melatonin-mediated oxidative stress regulation.
- Using a biocompatible protein (HSA) nanocarrier for the delivery of melatonin to the brain, researchers have proved that the nano-melatonin resulted in a sustained release of melatonin and improved bioavailability.
(Source: PIB)
